Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Oncorus, Inc. (ONCR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.2400+0.0200 (+1.64%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.2200
Open1.2400
Bid1.1100 x 4000
Ask1.8700 x 1300
Day's Range1.2000 - 1.2600
52 Week Range1.0300 - 17.7900
Volume52,993
Avg. Volume134,472
Market Cap32.003M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Simply Wall St.

    One Oncorus, Inc. (NASDAQ:ONCR) insider upped their stake in the previous year

    Insiders were net buyers of Oncorus, Inc.'s ( NASDAQ:ONCR ) stock during the past year. That is, insiders bought more...

  • Benzinga

    Mid-Afternoon Market Update: Dow Surges 150 Points; Team Shares Drop

    Toward the end of trading Friday, the Dow traded up 0.42% to 36,071.48 while the NASDAQ rose 0.84% to 15,835.89. The S&P also rose, gaining 0.61% to 4,677.60. The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 47,693,510 cases with around 780,770 deaths. India confirmed a total of at least 34,414,180 cases and 462,690 deaths, while Brazil reported over 21,926,520 COVID-19 cases with 610,320 deaths. In total, there were at least 252,785,840 cases of

  • Benzinga

    Why Did Oncorus Shares Slump To 52-Week Low Today?

    Oncorus Inc (NASDAQ: ONCR) shares slumped after the company reported initial data for its investigational cancer therapy ONCR-177 from a Phase 1 trial in heavily pretreated patients with advanced, injectable solid tumors. ONCR-177 is a Herpes Simplex Virus (HSV) product candidate. In the dose-escalation portion of the trial, ONCR-17 was well tolerated with no dose-limiting toxicities. 4x108 PFU in 4 mL was selected as the recommended Phase 2 dose (RP2D). With four evaluable patients in the monot

Advertisement
Advertisement